Mucosal Healing with Anti-TNF Antibodies
Mucosal Healing with Anti-TNF Antibodies
复制标题
DOI：
10.1159/000341957
复制
发表时间：
2012-01-01
期刊：
影响因子：
3.2
通讯作者：
Peyrin-Biroulet, Laurent
中科院分区：
文献类型：
--
作者：
Chevaux, Jean-Baptiste;Vavricka, Stephan R.;Peyrin-Biroulet, Laurent
目前，粘膜愈合被视为临床试验的主要终点，并越来越多地用于临床治疗炎症性肠病患者。非核愈合的定义在不同的研究中有所不同，并且仍然缺乏有效的内窥镜评分指标。抗肿瘤坏死因子药物的出现改变了治疗炎症性肠病的方式，使用这类药物可以实现高诱导和维持非核愈合率。粘膜愈合是可取的，因为它可以通过减少溃疡性结肠炎和克罗恩病的手术和住院率来改变疾病的自然进程。巴塞尔S. Karger股份有限公司版权所有
Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of nnucosal healing varies across studies and validated endoscopic scoring indices are still lacking. The advent of anti-tumor necrosis factor agents has changed the way of treating inflammatory bowel disease and high rates of induction and maintenance of nnucosal healing can be achieved with this drug class. Mucosal healing is desirable as it may change the natural course of the disease by decreasing surgery and hospitalization rates in both ulcerative colitis and Crohn's disease. Copyright (C) 2012 S. Karger AG, Basel